Inactive Instrument

QSAM Biosciences, Inc.

QSAM

US74738N2027

Biotechnology & Medical Research

QSAM Biosciences, Inc. Moves Its Official Headquarters from Palm Beach, Florida to Austin, Texas

January 28, 2021 at 04:15 pm

On January 27, 2021, the QSAM Biosciences, Inc. moved its official headquarters from Palm Beach, Florida to Austin, Texas.

Latest news about QSAM Biosciences, Inc.

Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	05-02	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	11-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding	23-09-28	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	23-06-14	CI
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	23-05-23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	23-04-26	CI
QSAM Biosciences Inc. Opens Enrollment of Second Cohort of Patients in its Phase 1 Study of CycloSam®? Targeting Metastatic Bone Cancer	23-04-05	CI
QSAM Biosciences, Inc. announced that it has received $3 million in funding	23-03-30	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
QSAM Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of Cyclosam(R) Targeting Metastatic Bone Cancer	23-03-08	CI
QSAM Biosciences, Inc. Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer	23-02-28	CI
QSAM Biosciences, Inc. Recruits the Ellis Fischel Cancer Center At the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam for Bone Cancer	23-02-22	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
QSAM Biosciences, Inc Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer	22-10-26	CI
QSAM Biosciences, Inc. announced a financing transaction	22-09-29	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
QSAM Biosciences, Inc. Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam	22-07-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
QSAM Biosciences, Inc. Announces the First Patient Commenced Treatment in Its Clinical Trial Evaluating Cyclosam® in Patients with Metastatic Bone Cancer	22-04-28	CI
QSAM Biosciences Inc. Receives Japanese Patent for Its Clinical Stage Radiopharmaceutical Drug Candidate, Cyclosam	22-04-12	CI

QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Companyâs technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research